Press release
Myositis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023
DelveInsight's, "Myositis Pipeline Insight 2023," report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Myositis pipeline landscape. It covers the Myositis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myositis Pipeline Report
• DelveInsight's Myositis pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Myositis treatment.
• The leading companies working in the Myositis Market include Pharmaceuticals, Janssen Research & Development, LLC, Pfizer, Abcuro, Inc., Orphazyme, Bristol-Myers Squibb, Kezar Life Sciences, Inc., Horizon Therapeutics, Paean Biotechnology Inc., Alexion Pharmaceuticals, ImmunoForge, JN Biosciences, Merck KGaA, and others.
• Promising Myositis Pipeline Therapies in the various stages of development includes ABC008, Daxdilimab, BYM338 (Bimagrumab), BYM338, Arimoclomol, Nipocalimab, Glucocorticoids, and others.
• On August 2023, Abcuro Inc. announced a study of Phase 2 & 3 clinical trials for ABC008. A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis.
• On August 2023, Horizon Therapeutics Ireland DAC announced a study of Phase 2 Clinical Trials for Daxdilimab. To evaluate the effect of daxdilimab compared with placebo in reducing disease activity at Week 24.
Request a sample and discover the recent advances in Myositis Treatment Drugs @ Myositis Pipeline Report- https://www.delveinsight.com/report-store/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The Myositis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Myositis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Myositis clinical trial landscape.
Myositis Overview
The term "myositis" refers to a general inflammation or swelling of the muscle. Many people have experienced sore muscles after vigorous exercise, a condition that is temporary and improves with rest.
Find out more about Myositis Treatment Landscape @ Drugs for Myositis Treatment- https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Myositis Emerging Drugs Profile
• Lenabasum: Corbus Pharmaceuticals
• Nipocalimab: Janssen Research & Development, LLC
Myositis Pipeline Therapeutics Assessment
There are approx. 20+ key companies which are developing the therapies for Myositis. The Myositis companies which have their Myositis drug candidates in the most advanced stage, i.e. phase III include, Corbus Pharmaceuticals.
Learn more about the emerging Myositis Pipeline Therapies @ Myositis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Myositis Pipeline Report
• Coverage- Global
• Allergic Conjunctivitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Allergic Conjunctivitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Myositis Companies- Corbus Pharmaceuticals, Janssen Research & Development, LLC, Pfizer, Abcuro, Inc., Orphazyme, Bristol-Myers Squibb, Kezar Life Sciences, Inc., Horizon Therapeutics, Paean Biotechnology Inc., Alexion Pharmaceuticals, ImmunoForge, JN Biosciences, Merck KGaA, and others.
• Myositis Pipeline Therapies- ABC008, Daxdilimab, BYM338 (Bimagrumab), BYM338, Arimoclomol, Nipocalimab, Glucocorticoids, and others.
Dive deep into rich insights for new drugs for Myositis Treatment, Visit @ Myositis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Myositis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Myositis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Lenabasum: Corbus Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Nipocalimab: Janssen Research & Development, LLC
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Myositis Key Companies
18. Myositis Key Products
19. Myositis- Unmet Needs
20. Myositis- Market Drivers and Barriers
21. Myositis- Future Perspectives and Conclusion
22. Myositis Analyst Views
23. Myositis Key Companies
24. Appendix
For further information on the Myositis Pipeline therapeutics, reach out to Myositis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Important Published Links
https://scocial-online.mn.co/posts/46864423
https://akb.tribe.so/post/behcet-s-disease-a-rare-and-chronic-inflammatory-condition-has-long-posed-c--6576dd3288d020256754898b
https://www.sutori.com/en/denny-dones?tab=profile
https://network-96590.mn.co/posts/46865392
https://lean-in-bay-area.mn.co/posts/46865790
https://network-88594.mn.co/posts/46865905
https://decide.mn.co/posts/46866036
https://jomijomig.mn.co/posts/46866708
https://constantlycheeky.mn.co/posts/46867239
https://www.vwvortex.com/members/ybhardwaj.3957496/#about
https://redline-rp.mn.co/posts/46868784
https://forum.eset.com/profile/88964-denny-dones/?tab=field_core_pfield_11
https://en.pinkoi.com/user/gg_116344212900924579142
https://dennydones9.diary.ru/
https://slideslive.com/ewkwsgtt7o?tab=about
https://dennydones.substack.com/p/behcets-syndrome-market-size-in-the?r=33xju7&utm_campaign=post&utm_medium=web
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market
Key Takeaways from the Myositis Pipeline Report
• DelveInsight's Myositis pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Myositis treatment.
• The leading companies working in the Myositis Market include Pharmaceuticals, Janssen Research & Development, LLC, Pfizer, Abcuro, Inc., Orphazyme, Bristol-Myers Squibb, Kezar Life Sciences, Inc., Horizon Therapeutics, Paean Biotechnology Inc., Alexion Pharmaceuticals, ImmunoForge, JN Biosciences, Merck KGaA, and others.
• Promising Myositis Pipeline Therapies in the various stages of development includes ABC008, Daxdilimab, BYM338 (Bimagrumab), BYM338, Arimoclomol, Nipocalimab, Glucocorticoids, and others.
• On August 2023, Abcuro Inc. announced a study of Phase 2 & 3 clinical trials for ABC008. A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis.
• On August 2023, Horizon Therapeutics Ireland DAC announced a study of Phase 2 Clinical Trials for Daxdilimab. To evaluate the effect of daxdilimab compared with placebo in reducing disease activity at Week 24.
Request a sample and discover the recent advances in Myositis Treatment Drugs @ Myositis Pipeline Report- https://www.delveinsight.com/report-store/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The Myositis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Myositis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Myositis clinical trial landscape.
Myositis Overview
The term "myositis" refers to a general inflammation or swelling of the muscle. Many people have experienced sore muscles after vigorous exercise, a condition that is temporary and improves with rest.
Find out more about Myositis Treatment Landscape @ Drugs for Myositis Treatment- https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Myositis Emerging Drugs Profile
• Lenabasum: Corbus Pharmaceuticals
• Nipocalimab: Janssen Research & Development, LLC
Myositis Pipeline Therapeutics Assessment
There are approx. 20+ key companies which are developing the therapies for Myositis. The Myositis companies which have their Myositis drug candidates in the most advanced stage, i.e. phase III include, Corbus Pharmaceuticals.
Learn more about the emerging Myositis Pipeline Therapies @ Myositis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Myositis Pipeline Report
• Coverage- Global
• Allergic Conjunctivitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Allergic Conjunctivitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Myositis Companies- Corbus Pharmaceuticals, Janssen Research & Development, LLC, Pfizer, Abcuro, Inc., Orphazyme, Bristol-Myers Squibb, Kezar Life Sciences, Inc., Horizon Therapeutics, Paean Biotechnology Inc., Alexion Pharmaceuticals, ImmunoForge, JN Biosciences, Merck KGaA, and others.
• Myositis Pipeline Therapies- ABC008, Daxdilimab, BYM338 (Bimagrumab), BYM338, Arimoclomol, Nipocalimab, Glucocorticoids, and others.
Dive deep into rich insights for new drugs for Myositis Treatment, Visit @ Myositis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Myositis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Myositis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Lenabasum: Corbus Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Nipocalimab: Janssen Research & Development, LLC
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Myositis Key Companies
18. Myositis Key Products
19. Myositis- Unmet Needs
20. Myositis- Market Drivers and Barriers
21. Myositis- Future Perspectives and Conclusion
22. Myositis Analyst Views
23. Myositis Key Companies
24. Appendix
For further information on the Myositis Pipeline therapeutics, reach out to Myositis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Important Published Links
https://scocial-online.mn.co/posts/46864423
https://akb.tribe.so/post/behcet-s-disease-a-rare-and-chronic-inflammatory-condition-has-long-posed-c--6576dd3288d020256754898b
https://www.sutori.com/en/denny-dones?tab=profile
https://network-96590.mn.co/posts/46865392
https://lean-in-bay-area.mn.co/posts/46865790
https://network-88594.mn.co/posts/46865905
https://decide.mn.co/posts/46866036
https://jomijomig.mn.co/posts/46866708
https://constantlycheeky.mn.co/posts/46867239
https://www.vwvortex.com/members/ybhardwaj.3957496/#about
https://redline-rp.mn.co/posts/46868784
https://forum.eset.com/profile/88964-denny-dones/?tab=field_core_pfield_11
https://en.pinkoi.com/user/gg_116344212900924579142
https://dennydones9.diary.ru/
https://slideslive.com/ewkwsgtt7o?tab=about
https://dennydones.substack.com/p/behcets-syndrome-market-size-in-the?r=33xju7&utm_campaign=post&utm_medium=web
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage
to this press release on woodPRI. woodPRI disclaims liability for any content contained in
this release.
Recommend
/newsMicroencapsulation Market Deep Analysis on Key Players - Dow Corning, Encapsys, Syngenta Crop Protection, Evonik Industries, 3M and Bayer
Market Study Report Adds Global Microencapsulation Market Size, Status and Forecast 2024 added to its database. The report provides key statistics on the current state of the industry and other analytical data to understand the market.
Extensive research is required for choosing the appropriate cor...
/newsGermany Airbag Market Size 2023: Global Share, Industry And Report Analysis By 2030 | Hyundai Mobis Co., Ltd. Key Safety Systems, Inc. Robert Bosch GmbH
Germany airbag market is expected to grow at a CAGR of around 6% during the forecast period. Germany Airbag Market research report refers to gathering and analyzing significant market data serve as best medium for various industry players to launch novel product or service. It is vital for key firms...
/newsSecurities Brokerages And Stock Exchanges Market Outlook 2021: Big Things are Happening
A new intelligence report released by HTF MI with title "Global Securities Brokerages And Stock Exchanges Market Survey & Outlook" is designed covering micro level of analysis by Insurers and key business segments, offerings and sales channels. The Global Securities Brokerages And Stock Exchange...
/newsRenewable Chemicals Market Emerging Trends and Competitive Landscape Forecast to 2028
The renewable chemicals market was valued at US$ 80,566.30 million in 2021 and is projected to reach US$ 1,76,750.76 million by 2028 it is expected to grow at a CAGR of 11.9% from 2021 to 2028. The research report focuses on the current market trends, opportunities, future potential of the market, a...
/newsHow Coronavirus is Impacting Cold Brew Coffee, Global Market Volume Analysis, Size, Share and Key Trends 2020-2026
"Market Latest Research Report 2020:
Los Angles United States, February 2020: The Cold Brew Coffee market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Research's lates...
/newsCorporate E-Learning Market - Global Industry Size, Share, Key Players Analysis that are Infor, SkillSoft Corporation, Adrenna, CERTPOINT Systems and others with Regional Forecast to 2022
Overview:
E-Learning is used to enhance the learning procedures for newer job requirements and to make employees sound about the internal and external changes in the market and respective organizations. This method has created considerable differences in the ways of training and developing employee...
